Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...

New schizophrenia drug Cobenfy offers hope with fewer side effects targeting symptoms more effectively than traditional ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

Clinical trials showed a new drug Cobenfy could address positive and negative symptoms and improve cognitive issues in some ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

Bristol-Myers Squibb Company (BMY) shares rose 1.6% after the FDA approved its new drug for schizophrenia. Shares of Cassava Sciences (SAVA) plunged 10.6% after the company reached a $40 million ...

New drug for schizophrenics has experts excited Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades. "This drug takes ...